SynthesisOral and maxillofacial surgery2025
Mandibular reconstruction with custom-made extended total temporomandibular joint prosthesis after resection of ameloblastoma:A systematic review.
Synthesis in Oral and maxillofacial surgery, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
8 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
objectivesAmeloblastoma (AB) are aggressive odontogenic tumors, often treated with wide marginal resection and concurrent reconstruction. Extended total temporomandibular joint replacement (eTMJR) prosthesis is a viable treatment option for reconstruction of large defects caused by resection of AB tumors. The objective of this study was to systematically review the utilization and effectiveness of eTMJR prosthesis in treating patients with AB tumors.
methodsA detail search in Web of Science, Medline/PubMed, Google Scholar and Embase identified studies reporting AB patients who underwent implantation of eTMJR prosthesis. Studies reporting the use of eTMJR prosthesis in the management of AB tumors were eligible, with no restriction of the study type, language or year of publication and patient's demographics. Quality assessment of the selected case reports and case series was carried out with the 13 Domains (30 Items) of the CARE checklist, using a scoring scale of "0" (No/ non-adherence), "1" (Yes/ adherence) and "2" (unclear). The completeness of reporting (COR) score was determined as the ratio of "yes" responses to "total" (i.e., yes + no + unclear) responses.
resultsA total of 27 studies were selected for analysis, including 15 case reports, 06 case series and 06 retrospective cohort studies. These studies presented 41 patients of AB who received eTMJR prosthesis. The patients' mean age was 37.8 ± 14.9 (range: 14-72, median: 36) years, whereas the mean follow-up period was 19.7 ± 20.3 (range: 1-84, median 12) months. The majority of studies did not document all clinically relevant data regarding patient clinical presentation, surgical procedures, long-term follow-up and post-operative complications. The mean ± SD (range, median) COR score for all case reports/ series was 61.7 ± 23.5 (4.0-100, 64.0) %.
conclusionThe use of eTMJR prosthesis in the management of AB tumors has demonstrated promising treatment outcome in case reports/ series. However, large cohort randomized controlled trials are essential to establish their therapeutic efficacy.
Indexed as
Identifiers
40973830What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.